Inovio Pharmaceuticals
NYSE/NASDAQ:INOPharmaPlymouth, Pennsylvania, United States · Est. 1998 · 300 employees
Inovio Pharmaceuticals is a biotechnology company developing DNA-based immunotherapies and vaccines for cancer and infectious diseases.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
2
Indications↗
Distinct diseases across all programs
27
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
No phase data available.
By Therapeutic Area
top 1
Oncology
1100%
R&D Momentum
12/100
Pipeline Velocity
0/100
Trial Completion Rate
92/100
Pipeline Concentration
100/100
Pipeline Freshness
19/100
Activity
Key Events
May 20, 20268-KINOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Oct 1, 2022TrialSafety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
Jun 21, 2021TrialSafety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
Jan 27, 2021TrialDose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
Nov 30, 2020TrialSafety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
Jun 15, 2020TrialINO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Apr 3, 2020TrialSafety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
May 9, 2019TrialSafety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
4 more events
Feb 28, 2019TrialREVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
May 31, 2018TrialINO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
May 24, 2018TrialINO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
May 15, 2018TrialVGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Details
Company Info
Company Overview
$150.0M
Mkt Cap
$40.6M
Revenue
$65.8M
Cash
CEOPeter Lis
Founded1998
Employees300
HQPlymouth, Pennsylvania, United States
ExchangeNYSE/NASDAQ:INO
Websiteinovio.com
LinkedInCompany Page
Therapeutic Focus
OncologyImmunologyInfectious Disease
Recent SEC Filings
8-KMay 20, 2026
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Glioblastoma
INO-5401Phase 2
Urothelial Carcinoma
INO-5401Phase 2
Regulatory
Regulatory Timeline
20261 event
SECMay 20
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Accession: 001-14888
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)